A study from theDepartment of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USAhas reported that“miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.”
This study was published in theJune 25, 2014Nature[I.F >35]byProf. Wan Y,Krzeszinskiand others fromtheDepartment of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
On the foundation of this interesting finding,Dr L Boominathan,Director-cum-chief Scientist of GBMD,reports here that:Molecular and Therapeutic insights into Osteoclastogenesis and its associated disorders: Tumor suppressor ARF inhibits osteoporosis and bone metastasis.This study may suggest that ARF, by up regulating its target gene, it may suppress the expression of Tgif2. Together, this study suggests thatpharmacological formulations encompassing “ARF activators” can be used to inhibit osteoporosis and bone metastasis.
Idea Proposed/Formulatedby:Dr L Boominathan PhD
Terms & Conditionsapplyhttp://genomediscovery.org/registration/terms-and-conditions/
Courtesy:When you cite drop us a line firstname.lastname@example.org
Citation:Boominathan,Molecular and Therapeutic insights into Osteoclastogenesis and its associated disorders: Tumor suppressor ARFinhibits osteoporosis and bone metastasis, 25/July/2014, 06.03 am, Genome-2-Bio-MedicineDiscovery center(GBMD),http://genomediscovery.org